CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 51 - 60 of 1130
Study Number Lead Group Study Title CIRB Study Status
10200 ETCTN A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis Completed
10204 ETCTN A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) Adult CIRB - Early Phase Emphasis Available to Open
10208 ETCTN A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma Adult CIRB - Early Phase Emphasis Available to Open
10211 ETCTN A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer Adult CIRB - Early Phase Emphasis Available to Open
10212 ETCTN A Phase 1b/2 study of Pinometostat in Combination with standard induction chemotherapy in newly diagnosed Acute Myeloid Leukemia with MLL rearrangement Adult CIRB - Early Phase Emphasis Completed
10214 ETCTN Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers Adult CIRB - Early Phase Emphasis Available to Open
10216 ETCTN A Phase I/II Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer Adult CIRB - Early Phase Emphasis Available to Open
10217 ETCTN A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10218 ETCTN A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma Adult CIRB - Early Phase Emphasis Available to Open
10219 ETCTN Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Adult CIRB - Early Phase Emphasis Available to Open
Displaying 51 - 60 of 1130